STRATA Skin Sciences, Inc. Q3 2025 Earnings Recap

SSKN Q3 2025 November 14, 2025

Get alerts when SSKN reports next quarter

STRATA Skin Sciences reported a challenging third quarter with revenues decreasing by 20% year-over-year, largely due to international market pressures, while domestic recurring revenues demonstrate resilience and growth.

Earnings Per Share Miss

$-0.36 vs $-0.26 est.

-38.5% surprise

Revenue Miss

6929000 vs 8492000 est.

-18.4% surprise

Market Reaction

1-Day +7.35%

5-Day -8.09%

30-Day -4.41%

See SSKN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue for Q3 2025 was $6.9 million, a decline of 20% compared to Q3 2024, primarily impacted by international trade uncertainties.
U.S. recurring revenue from XTRAC increased by 2.8%, signaling stability within domestic operations.
The expanded CPT codes for XTRAC treatments, effective January 2027, offer potential access to over 30 million patients, significantly enlarging the company’s market opportunity.
The Elevate360 program has driven an average clinic growth rate of 7% year-over-year and improved gross billings per device by 8.5% compared to last year.
STRATA is pursuing legal action against LaserOptik, anticipating significant damages that could bolster revenue from previously misled clinics.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SSKN on AllInvestView.